Resources
11 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/24/2022 (updated 3/27/2024)
Use the search engine above maintained by the DEA to find permanent drug disposal locations.
Posted 3/14/2023 (updated 3/27/2024)
The Drug Enforcement Administration (DEA) announced proposed rules for the prescribing of controlled medications via telemedicine beyond the end of the COVID-19 public health emergency. One rule addresses the expansion of induction of buprenorphine via telemedicine encounter while the other covers telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation. While opioid use disorders occur at similar rates in both rural and urban areas, medication assisted treatment (MAT) prescribers have been disproportionately located in urban areas. The public will be able to comment on the proposed rules until March 31st.
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 4/14/2023 (updated 3/27/2024)
The next National Prescription Drug Take Back Day is on April 22, 2023. If you have unused or expired prescription medications, you can locate a safe and convenient disposal drop off location using the U.S Drug Enforcement Association's (DEA) website. The DEA aims to help the public remove unneeded medications from their homes as a measure of preventing medication misuse and opioid addiction from ever starting.
Posted 12/13/2022 (updated 3/27/2024)
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.
Posted 7/21/2023 (updated 3/28/2024)
The Office of National Drug Control Policy (ONDCP) released a plan in response to fentanyl being adulterated or associated with xylazine, which was declared as an emerging drug threat in April 2023. Due to the effect of combining these substances, people may be less responsive to naloxone in an overdose situation. The response plan includes evidence-based prevention, treatment, and supply reduction action steps, goals, and performance measures.
Posted 7/26/2023 (updated 3/28/2024)
Upon the completion of this workshop, participants recognized ONDCP’s National Drug Control Strategy prevention priorities; understand the DFC Program’s Mode and the funding process; and be able to identify a DFC-funded coalition near them.
Posted 2/10/2020 (updated 3/28/2024)
ONDCP released a new tool to assist rural community leaders in building an effective local response to the crisis of addiction, the Rural Community Action Guide: Building Stronger, Healthy Drug-Free Rural Communities. The Guide also has a companion supplement, a listing of promising practices, included.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.